^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
JNJ-26483327
i
Other names: JNJ-26483327
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
J&J
Drug class:
EGFR inhibitor, HER2 inhibitor, HER4 inhibitor, Src kinase inhibitor, RET inhibitor, VEGFR-3 inhibitor
Related drugs:
over1year
GASTRIC INTESTINAL METAPLASIA VS GASTRIC ADENOCARCINOMA IN PATIENTS: DISTINCT PHENOTYPIC TRAITS IN TRANSCRIPTOMICS (DDW 2023)
The results of the present study did not support the dogma that GIM is the essential precancerous lesion in GA tumorigenesis and suggested possible drug repurposing for treatment of GIM.
Clinical • BRCA Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BRCA1 (Breast cancer 1, early onset) • CD8 (cluster of differentiation 8) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-DPA1 (Major Histocompatibility Complex, Class II, DP Alpha 1) • HNF1A (HNF1 Homeobox A) • PPARGC1A (PPARG Coactivator 1 Alpha) • RBP2 (Retinol Binding Protein 2)
|
dasatinib • JNJ-26483327
Share via
